Dengue to Zika: WHO’s new plan to tackle mosquito-borne diseases has these 6 pointers we all must know

Mosquitoes are no longer just a seasonal problem; they’re a full-blown health threat. With climate change, crowded cities, and people moving more than ever before, viruses like dengue, chikungunya, Zika, and yellow fever are finding new homes across the globe. Over 5.6 billion people are now at risk, that’s nearly 70% of the world. Recognising the need for a global reset in how these diseases are handled, the World Health Organisation (WHO) has released its first-ever guideline for the clinical management of these 4 arboviral diseases (a set of illnesses caused by viruses that are spread among humans by the bites of infected arthropods, mostly mosquitoes and ticks).
The message is clear: these illnesses may look the same in the beginning, but the response needs to be smarter, faster, and uniform worldwide.

The focus is on 4 major arboviral diseases, dengue, chikungunya, Zika, and yellow fever, all spread by the Aedes aegypti mosquito. These diseases mostly show up with similar symptoms: fever, body pain, rashes, and joint swelling. That’s what makes them so dangerous, they’re easy to mistake for each other, especially when diagnostic tests aren't available.

But the risk doesn’t end with just feeling sick. If not cured correctly, they can turn serious fast. Dengue, for example, can lead to internal bleeding. Yellow fever can attack the liver. Zika may cause birth defects. Chikungunya, though rarely fatal, can lead to long-term joint pain that feels like arthritis.

This is why WHO’s unified protocol can be a game-changer, a single framework that would help doctors manage these infections more efficiently, especially in places where resources are stretched thin.

The guidelines separate treatment based on how severe the illness is: mild cases vs hospitalised or severe cases. And every suggestion comes from the latest global evidence.

For mild or early-stage cases:

Stick to oral fluids; dehydration is one of the biggest early risks.
Use paracetamol or metamizole; these help bring down fever and pain safely.
Avoid NSAIDs like ibuprofen, as they increase bleeding risk, especially with dengue.
Skip corticosteroids, they do more harm than good in non-severe cases.

Use crystalloid fluids for IV hydration, safer than colloids for stabilising patients.
Check capillary refill time and lactate levels, to track how the body is responding.
Use passive leg raise test for shock; a quick test to assess fluid needs.
Avoid platelet transfusions unless there’s active bleeding; low count isn’t reason enough.
For yellow fever-related liver failure, IV N-acetylcysteine is now part of the management.
Experimental therapies like monoclonal antibodies? Use them only in research settings for now.

What’s critical here is that old methods based on guesswork are being replaced by a unified strategy that health workers can now rely on, whether they’re in urban hospitals or rural clinics.

This is not just about better treatment, it’s about preventing health systems from collapsing during outbreaks. Earlier, most WHO guidance came from expert opinions and fragmented evidence. That worked in the past, but not anymore.

Today, multiple arboviruses often hit the same region at once.
Diagnostic tools are still out of reach for many clinics.
New regions, even those without past experience, are now facing outbreaks due to changing climates.

This means clinicians without prior exposure to these diseases are left with guesswork. WHO’s new guideline offers a lifeline, especially to first-timers handling such outbreaks.

It also helps reduce hospital admissions and shorten recovery time, easing the burden on already strained healthcare systems.

[This article is for informational purposes only and does not replace professional medical advice. All recommendations mentioned are based on WHO’s official clinical management guidelines for arboviral diseases. Always consult healthcare professionals for any medical concerns or treatment plans.]